Elicio Therapeutics (ELTX) Liabilities and Shareholders Equity (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $22.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 19.48% year-over-year to $22.7 million; the trailing twelve-month figure through Mar 2026 stood at $106.4 million (down 3.74% YoY), and the FY2025 full-year result was $25.9 million, down 8.22% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $22.7 million, down from $25.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $81.3 million in Q1 2022 and bottomed at $15.8 million in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $28.3 million (2025), against an average of $36.2 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity tumbled 76.52%; it then surged 87.48% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $22.7 million in 2022, then increased by 19.78% to $27.1 million in 2023, then advanced by 3.8% to $28.2 million in 2024, then dropped by 8.22% to $25.9 million in 2025, then dropped by 12.27% to $22.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $22.7 million (Q1 2026), $25.9 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.

Peer Comparison